About This Video
In our exclusive interview, Geoff Dow, President and CEO of 60 Degrees Pharmaceuticals (Nasdaq: SXTP), breaks down the company’s commercial growth plan for ARAKODA® (tafenoquine) and the potential expansion into babesiosis, a tick-borne disease with no FDA-approved treatments today.
60 Degrees Pharma is already revenue-generating and is working to scale ARAKODA while advancing tafenoquine into a larger adjacent indication. The company also shared an early signal in its relapsing babesiosis study, reporting no Babesia infection detected in the first patient to complete therapy (reported October 2025).
60 Degrees Pharma is already revenue-generating and is working to scale ARAKODA while advancing tafenoquine into a larger adjacent indication. The company also shared an early signal in its relapsing babesiosis study, reporting no Babesia infection detected in the first patient to complete therapy (reported October 2025).